Astuprotimut-r clinical trials
Also written MAGE-A3 ASCI.
How each study uses astuprotimut-r is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 2 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 4
GlaxoSmithKline (5) · M.D. Anderson Cancer Center (1) · University of Maryland, Baltimore (1) · Patrice Jichlinski (1) · University of Arkansas (1)
Often tested with
Tested in the same studies.
Melanoma-associated antigen 3 (3) · Melanoma-Associated Antigen 3 (3) · Interleukin-2 (1) · HPV16 Vaccine (1)
Studies
Open first, then newest update. How each study uses astuprotimut-r is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous MelanomaCompletedPhase 2GlaxoSmithKlineNCT00896480Written as Immunotherapeutic GSK2132231A
- GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung CancerTerminatedPhase 3GlaxoSmithKlineNCT00480025Written as GSK1572932A Antigen-Specific Cancer Immunotherapeutic
- A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced MelanomaCompletedPhase 2GlaxoSmithKlineNCT00942162Written as Immunotherapeutic GSK2132231A
- High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCICompletedPhase 2M.D. Anderson Cancer CenterNCT01266603Written as recMAGE-A3 + AS15
- Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by SurgeryCompletedPhase 2GlaxoSmithKlineNCT00290355Written as GSK 249553 vaccine
- 0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and NeckCompletedPhase 1University of Maryland, BaltimoreNCT00257738Written as MAGE-A3
- Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung CancerTerminatedPhase 1GlaxoSmithKlineNCT00455572Written as Immunotherapeutic GSK1572932A
- BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) PatientsCompletedPhase 1Patrice JichlinskiNCT01498172Written as MAGE-A3 ASCI
- Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple MyelomaCompletedPhase 2/3University of ArkansasNCT00090493Written as MAGE-A3
Codes
What other systems call astuprotimut-r · ClinicalTrials.gg INT014961
- UNII (FDA) 50I23C5UORASTUPROTIMUT-ROne source FDA
- NCI Thesaurus C78478Astuprotimut-ROne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 50I23C5UOR | ASTUPROTIMUT-R | One source FDA |
| NCI Thesaurus | C78478 | Astuprotimut-R | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.